Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 154 No. 7 (2024)

Interdisciplinary strategies for diagnosis and treatment of trigeminal neuralgia

DOI
https://doi.org/10.57187/s.3460
Cite this as:
Swiss Med Wkly. 2024;154:3460
Published
24.07.2024

Summary

Temporary, sudden, shooting and recurrent unilateral facial pain in the supply area of one or more trigeminal nerve branches characterises trigeminal neuralgia. Innocuous stimuli trigger the pain, e.g. chewing, speaking or brushing teeth. In some patients, paroxysms superimpose on continuous pain. In aetiological terms, idiopathic, classic (due to neurovascular compression) and secondary trigeminal neuralgia (e.g. due to multiple sclerosis, brainstem ischaemia and space-occupying lesions) are defined. Many drugs may be efficacious, with carbamazepine being first-choice therapy. However, non-pharmacological and invasive procedures may also help. To reach the correct diagnosis and determine the best therapeutic measures, adequate pain characterisation and interdisciplinary collaboration are essential. We hereby present our experience of an interdisciplinary approach for the diagnosis and treatment of trigeminal neuralgia.

References

  1. Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal Neuralgia: Basic and Clinical Aspects. Curr Neuropharmacol. 2020;18(2):109–19. 10.2174/1570159X17666191010094350 DOI: https://doi.org/10.2174/1570159X17666191010094350
  2. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia—a prospective systematic study of clinical characteristics in 158 patients. Headache. 2014;54(10):1574–82. 10.1111/head.12441 DOI: https://doi.org/10.1111/head.12441
  3. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. Clin J Pain. 2002;18(1):4–13. 10.1097/00002508-200201000-00002 DOI: https://doi.org/10.1097/00002508-200201000-00002
  4. Barker FG 2nd, Jannetta PJ, Bissonette DJ, Larkins MV, Jho HD. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996 Apr;334(17):1077–83. 10.1056/NEJM199604253341701 DOI: https://doi.org/10.1056/NEJM199604253341701
  5. Martinelli Boneschi F, Colombo B, Annovazzi P, Martinelli V, Bernasconi L, Solaro C, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008 May;14(4):514–21. 10.1177/1352458507085551 DOI: https://doi.org/10.1177/1352458507085551
  6. Di Stefano G, Maarbjerg S, Truini A. Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options. J Headache Pain. 2019 Feb;20(1):20. 10.1186/s10194-019-0969-0 DOI: https://doi.org/10.1186/s10194-019-0969-0
  7. Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. BMJ. 2007 Jan;334(7586):201–5. 10.1136/bmj.39085.614792.BE DOI: https://doi.org/10.1136/bmj.39085.614792.BE
  8. Katusic S, Beard CM, Bergstralh E, Kurland LT. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990 Jan;27(1):89–95. 10.1002/ana.410270114 DOI: https://doi.org/10.1002/ana.410270114
  9. Ruscheweyh R, Lutz J, Mehrkens JH. Trigeminusneuralgie : Moderne Diagnostik und Therapie [Trigeminal neuralgia : Modern diagnostic workup and treatment]. Schmerz. 2020 Dec;34(6):486–94. 10.1007/s00482-020-00496-4 DOI: https://doi.org/10.1007/s00482-020-00496-4
  10. Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PR, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020 Sep;19(9):784–96. 10.1016/S1474-4422(20)30233-7 DOI: https://doi.org/10.1016/S1474-4422(20)30233-7
  11. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202 DOI: https://doi.org/10.1177/0333102417738202
  12. Masur H, Papke K, Bongartz G, Vollbrecht K. The significance of three-dimensional MR-defined neurovascular compression for the pathogenesis of trigeminal neuralgia. J Neurol. 1995 Jan;242(2):93–8. 10.1007/BF00887823 DOI: https://doi.org/10.1007/BF00887823
  13. Peker S, Dinçer A, Necmettin Pamir M. Vascular compression of the trigeminal nerve is a frequent finding in asymptomatic individuals: 3-T MR imaging of 200 trigeminal nerves using 3D CISS sequences. Acta Neurochir (Wien). 2009 Sep;151(9):1081–8. 10.1007/s00701-009-0329-y DOI: https://doi.org/10.1007/s00701-009-0329-y
  14. Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019 Jun;26(6):831–49. 10.1111/ene.13950 DOI: https://doi.org/10.1111/ene.13950
  15. von Eckardstein KL, Keil M, Rohde V. Unnecessary dental procedures as a consequence of trigeminal neuralgia. Neurosurg Rev. 2015 Apr;38(2):355–60. 10.1007/s10143-014-0591-1 DOI: https://doi.org/10.1007/s10143-014-0591-1
  16. Maltez N, Choi MY, Troyanov Y, Wang M, Jantz M, Fritzler MJ, et al.; Canadian Scleroderma Research Group. Trigeminal neuralgia in systemic sclerosis. Semin Arthritis Rheum. 2021 Feb;51(1):318–23. 10.1016/j.semarthrit.2021.01.001 DOI: https://doi.org/10.1016/j.semarthrit.2021.01.001
  17. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000 Apr;123(Pt 4):665–76. 10.1093/brain/123.4.665 DOI: https://doi.org/10.1093/brain/123.4.665
  18. Maikap D, Padhan P. Trigeminal Neuralgia as an Initial Presentation of Systemic Autoimmune Diseases: A Case Series. Mediterr J Rheumatol. 2022;33(3):333-338. Published 2022 Sep 30. doi:10.31138/mjr.33.3.333 DOI: https://doi.org/10.31138/mjr.33.3.333
  19. Nascimento IS, Bonfá E, de Carvalho JF, Saad CG, Vendramini MB, Teixeira MJ, et al. Clues for previously undiagnosed connective tissue disease in patients with trigeminal neuralgia. J Clin Rheumatol. 2010 Aug;16(5):205–8. 10.1097/RHU.0b013e3181e928e6 DOI: https://doi.org/10.1097/RHU.0b013e3181e928e6
  20. Scardina GA, Mazzullo M, Messina P. La diagnosi precoce della sclerosi sistemica progressiva. Il ruolo delle manifestazioni oro-facciali [Early diagnosis of progressive systemic sclerosis: the role of oro-facial phenomena]. Minerva Stomatol. 2002;51(7-8):311–7.
  21. Machet L, Vaillant L, Machet MC, Esteve E, Muller C, Khallouf R, et al. Carpal tunnel syndrome and systemic sclerosis. Dermatology. 1992;185(2):101–3. 10.1159/000247422 DOI: https://doi.org/10.1159/000247422
  22. Symonds T, Randall JA, Hoffman DL, Zakrzewska JM, Gehringer W, Lee JY. Measuring the impact of trigeminal neuralgia pain: the Penn Facial Pain Scale-Revised. J Pain Res. 2018 Jun;11:1067–73. 10.2147/JPR.S152958 DOI: https://doi.org/10.2147/JPR.S152958
  23. Sandhu SK, Halpern CH, Vakhshori V, Mirsaeedi-Farahani K, Farrar JT, Lee JY. Brief pain inventory—facial minimum clinically important difference. J Neurosurg. 2015 Jan;122(1):180–90. 10.3171/2014.8.JNS132547 DOI: https://doi.org/10.3171/2014.8.JNS132547
  24. Lee KH. Facial pain: trigeminal neuralgia. Ann Acad Med Singap. 1993 Mar;22(2):193–6.
  25. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004 Apr;428(6982):486. 10.1038/428486a DOI: https://doi.org/10.1038/428486a
  26. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011 Mar;364(12):1134–43. 10.1056/NEJMoa1013297 DOI: https://doi.org/10.1056/NEJMoa1013297
  27. Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012 Apr;32(6):443–50. 10.1177/0333102412441721 DOI: https://doi.org/10.1177/0333102412441721
  28. Zúñiga C, Piedimonte F, Díaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36(5):146–50. 10.1097/WNF.0b013e31829cb60e DOI: https://doi.org/10.1097/WNF.0b013e31829cb60e
  29. Morra ME, Elgebaly A, Elmaraezy A, Khalil AM, Altibi AM, Vu TL, et al. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016 Dec;17(1):63. 10.1186/s10194-016-0651-8 DOI: https://doi.org/10.1186/s10194-016-0651-8
  30. Liu J, Xu YY, Zhang QL, Luo WF. Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia. Pain Res Manag. 2018;2018:7365148. Published 2018 Apr 5. 10.1155/2018/7365148 DOI: https://doi.org/10.1155/2018/7365148
  31. Asan F, Gündüz A, Tütüncü M, Uygunoğlu U, Savrun FK, Saip S, et al. Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA. Headache. 2022 Nov;62(10):1322–8. 10.1111/head.14414 DOI: https://doi.org/10.1111/head.14414
  32. Schott Andersen AS, Maarbjerg S, Noory N, Heinskou TB, Forman JL, Cruccu G, et al. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol. 2022 Nov;21(11):994–1003. 10.1016/S1474-4422(22)00294-0 DOI: https://doi.org/10.1016/S1474-4422(22)00294-0
  33. Gambeta E, Chichorro JG, Zamponi GW. Trigeminal neuralgia: an overview from pathophysiology to pharmacological treatments. Mol Pain. 2020;16:1744806920901890. 10.1177/1744806920901890 DOI: https://doi.org/10.1177/1744806920901890
  34. Masrour S. Lacosamide for refractory trigeminal neuralgia and other facial pain-Case report. Headache. 2022 Oct;62(9):1227–30. 10.1111/head.14367 DOI: https://doi.org/10.1111/head.14367
  35. Muñoz-Vendrell A, Teixidor S, Sala-Padró J, Campoy S, Huerta-Villanueva M. Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases. Cephalalgia. 2022 Sep;42(10):1031–8. 10.1177/03331024221092435 DOI: https://doi.org/10.1177/03331024221092435
  36. Bick SK, Eskandar EN. Surgical Treatment of Trigeminal Neuralgia. Neurosurg Clin N Am. 2017 Jul;28(3):429–38. 10.1016/j.nec.2017.02.009 DOI: https://doi.org/10.1016/j.nec.2017.02.009
  37. Lee S, Lee JI. Gamma Knife Radiosurgery for Trigeminal Neuralgia : review and Update. J Korean Neurosurg Soc. 2022 Sep;65(5):633–9. 10.3340/jkns.2021.0303 DOI: https://doi.org/10.3340/jkns.2021.0303
  38. Rasche D, Tronnier VM. Clinical Significance of Invasive Motor Cortex Stimulation for Trigeminal Facial Neuropathic Pain Syndromes. Neurosurgery. 2016 Nov;79(5):655–66. 10.1227/NEU.0000000000001353 DOI: https://doi.org/10.1227/NEU.0000000000001353
  39. Ishaque M, Moosa S, Urban L, Kundu B, Qureshi Z, Spears T, et al. Bilateral focused ultrasound medial thalamotomies for trigeminal neuropathic pain: a randomized controlled study. J Neurosurg. 2023 Dec:1–11. 10.3171/2023.10.JNS23661 DOI: https://doi.org/10.3171/2023.10.JNS23661
  40. Taranta V, Saporito G, Ornello R, Splendiani A, Bruno F, Sucapane P, et al. Magnetic Resonance-guided Focused Ultrasound thalamotomy for refractory neuropathic pain: a systematic review and critical appraisal of current knowledge. Ther Adv Neurol Disord. 2023 Jun;16:17562864231180729. 10.1177/17562864231180729 DOI: https://doi.org/10.1177/17562864231180729
  41. Peñarrocha M, Cervelló MA, Martí E, Bagán JV. Trigeminal neuropathy. Oral Dis. 2007 Mar;13(2):141–50. 10.1111/j.1601-0825.2006.01356.x DOI: https://doi.org/10.1111/j.1601-0825.2006.01356.x
  42. Gierthmuehlen M, Gierthmuehlen P, Hugger A, Gierthmuehlen J, Türp JC. Neuropathische Gesichtsschmerzen – eine interdisziplinäre Herausforderung. Swiss Dent J. 2020 Apr;130(4):321–7. 10.61872/sdj-2020-04-03 DOI: https://doi.org/10.61872/sdj-2020-04-03
  43. Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al.; OPTION-DM trial group. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial [Erratum in: Lancet. 2022 Sep 10;400] [10355]. Lancet. 2022 Aug;400(10353):680–90. 10.1016/S0140-6736(22)01472-6 DOI: https://doi.org/10.1016/S0140-6736(22)01472-6
  44. Owen SL, Green AL, Nandi DD, Bittar RG, Wang S, Aziz TZ. Deep brain stimulation for neuropathic pain. Acta Neurochir Suppl (Wien). 2007;97(Pt 2):111–6. DOI: https://doi.org/10.1007/978-3-211-33081-4_13
  45. Pereira EA, Aziz TZ. Neuropathic pain and deep brain stimulation. Neurotherapeutics. 2014 Jul;11(3):496–507. 10.1007/s13311-014-0278-x DOI: https://doi.org/10.1007/s13311-014-0278-x

Most read articles by the same author(s)